Pharvaris Bundle
Can Pharvaris shift HAE care from injectables to an oral pill?
Pharvaris pioneered oral bradykinin B2-receptor antagonists for hereditary angioedema (HAE), advancing deucrictibant as both on-demand and prophylactic options. Phase 2 results showed rapid symptom relief and promise for convenient prevention in a field dominated by injectables.
Founded in the Netherlands in 2015, Pharvaris is a Nasdaq-listed clinical-stage biopharma with a late-stage, two-pronged oral HAE program and a cash runway into 2026. It plans expansion into bradykinin-mediated angioedema and broader indications.
What is Brief History of Pharvaris Company? Pharvaris emerged by advancing potent small-molecule oral antagonists, reported pivotal Phase 2 deucrictibant data, and now pursues late-stage development and strategic growth; see Pharvaris Porter's Five Forces Analysis.
What is the Pharvaris Founding Story?
Pharvaris was founded on September 24, 2015, by former Jerini/Shire HAE veterans and colleagues aiming to develop oral, needle-free therapies for hereditary angioedema (HAE), leveraging expertise from the icatibant (Firazyr) era to rival injectable standards and improve patient quality of life.
Founding Story
The founding nucleus combined medicinal chemistry, clinical development and rare-disease commercialization experience to pursue small-molecule B2-receptor antagonists for on-demand and preventive HAE care.
- Founded on September 24, 2015 by a team including Berndt Jung, Peng Lu, Anne Lesage, Jochen Knolle and CEO/co-founder Bernd Schellekens’ early collaborators.
- Founders brought prior experience from Jerini/Shire and the icatibant (Firazyr) era, informing an oral-first strategy for HAE treatment.
- Business model focused on developing small-molecule B2-receptor antagonists: deucrictibant immediate-release for acute attacks and deucrictibant extended-release for prophylaxis.
- Early financing (seed and Series A, 2016–2017) included investors BGV, Sofinnova Partners, NVF/Novartis Venture Fund and Gilde Healthcare, funding IND-enabling studies and Phase 1 trials.
Pharvaris aimed for market leadership in oral HAE care and platform extension to other bradykinin-mediated conditions; the name signaled pharmaceutical innovation, variance and versatility in rare diseases. Read more on the company’s mission and values: Mission, Vision & Core Values of Pharvaris
Pharvaris SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Pharvaris?
Early growth and expansion at Pharvaris focused on advancing deucrictibant from discovery into human trials, building R&D and CMC capabilities in the Netherlands, and scaling clinical programs and financing to support global development.
2016–2018: Discovery to first‑in‑human
Between 2016 and 2018 Pharvaris progressed deucrictibant from discovery to first‑in‑human studies, demonstrating safety, PK/PD, and B2‑receptor target engagement while establishing R&D operations in Leiden/Oegstgeest and filing early formulation IP.
2019–2021: Clinical scale and IPO
From 2019 to 2021 Pharvaris scaled into Phase 2 (PHVS416 immediate‑release softgel) and launched an extended‑release prophylactic program (PHVS719), closing a $190,000,000 Nasdaq IPO in February 2021 to fund global trials and manufacturing.
2022–2023: Regulatory adaptation
After a 2022 FDA clinical hold in the US, Pharvaris shifted execution to ex‑US centers, strengthened regulatory engagement, enhanced risk management and data packages, expanded leadership and clinical operations, and raised follow‑on capital and ATM liquidity.
2024–2025: Resumption and positioning
Post‑remediation Pharvaris resumed US studies; Phase 2 data supported on‑demand efficacy and once‑daily prophylaxis potential. The company entered 2025 with cash and equivalents reported in the hundreds of millions, providing runway into 2H 2026 to fund pivotal trials while refining commercial readiness versus existing HAE therapies.
Key tactical moves included prioritizing pivotal trial design alignment with regulators, preparing label‑enabling CMC and supply chain, and sharpening competitive differentiation against approved HAE options; further context in the Growth Strategy of Pharvaris.
Pharvaris PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Pharvaris history?
Milestones, Innovations and Challenges of the Pharvaris company history cover rapid oral HAE therapeutic development, IPO and financings, regulatory setbacks and eventual resumption of US trials, and a strategy focused on patient-centric oral alternatives to injectables.
| Year | Milestone |
|---|---|
| 2016 | Company founded to develop oral small-molecule bradykinin B2 receptor antagonists for hereditary angioedema. |
| 2021 | Completed IPO, raising capital to advance deucrictibant and PHVS719 into larger clinical programs. |
| 2022 | FDA placed a clinical hold on US trials, prompting ex-US execution and expanded preclinical work. |
| 2023 | Resumed global trials outside the US while strengthening IP and manufacturing scale-up for deucrictibant. |
| 2024 | Regulatory engagement led to lifting of key US constraints and resumption of US studies; market cap recovered above $1 billion during positive data and regulatory progress. |
| 2024–2025 | Reported Phase 1/2 data showing rapid symptom relief with PHVS416 IR and advanced PHVS719 ER into once-daily prophylactic studies. |
Key innovations include oral deucrictibant (PHVS416 IR softgel) showing rapid relief comparable in mechanism to injectable icatibant but as an oral small molecule, and PHVS719 ER as a once-daily prophylactic designed to improve adherence and convenience.
Oral Acute Therapy
Deucrictibant (PHVS416 IR softgel) delivered rapid onsets of symptom relief in Phase 1/2, with dose-ranging optimizing speed and durability versus baseline attack trajectories.
Once-Daily Prophylactic
PHVS719 ER advanced as an extended-release tablet targeting consistent exposure to reduce monthly attack frequency and improve real-world adherence.
Intellectual Property
Developed a robust IP estate around deucrictibant composition, formulations, and methods of use, supporting global development and potential commercialization.
Manufacturing Scale-Up
Scaled small-molecule manufacturing capabilities to support multi-regional clinical trials and anticipated commercial supply chains.
Regulatory Strategy
Engaged iteratively with regulators to convert an injectable-targeted axis into an oral-first program, informing trial design and endpoints.
Clinical Outcomes
Phase 1/2 programs reported clinically meaningful efficacy and safety profiles consistent with B2 antagonism, supporting further development.
Major challenges included a 2022 FDA clinical hold that paused US trials and increased costs, and competitive pressures from established injectable prophylactics and acute treatments requiring strong efficacy and patient-centric benefits to prompt switching.
Regulatory Hold
FDA clinical hold in 2022 compressed timelines and added expense; the company pursued ex-US trials, expanded preclinical data, and intensified FDA dialogue, leading to resolution and US trial resumption by 2024–2025.
Competitive Market
Faced established therapies like lanadelumab and icatibant; focused on patient-reported outcomes, onset-of-relief and attack-free days to demonstrate compelling advantages for oral options.
Financing Cyclicality
Biotech market volatility in 2022–2023 pressured cash planning; the company completed follow-on financings and prioritized R&D to extend runway into 2026, with market cap recovery tied to positive 2024–2025 milestones.
Clinical Differentiation
Needed head-to-head relevant endpoints to justify switching from injectables, leading to trial designs emphasizing rapid symptom relief and durable prevention metrics.
Manufacturing Readiness
Invested in small-molecule manufacturing scale-up to assure supply for registrational trials and future commercial demand, reducing execution risk.
Stakeholder Engagement
Strengthened payer, clinician and patient engagement to validate convenience and adherence benefits of oral therapies against established standards of care.
Relevant coverage and market context are summarized in this article: Target Market of Pharvaris
Pharvaris Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Pharvaris?
Timeline and Future Outlook: concise chronology of Pharvaris history, key clinical and financing milestones from 2015 founding through 2025 pivots, and projected 2026–2027 regulatory and commercial objectives.
| Year | Key Event |
|---|---|
| 2015 | Company founded in the Netherlands to develop oral therapies for HAE via B2-receptor antagonism. |
| 2016 | Seed/Series A financing from Sofinnova, BGV, Novartis Venture Fund and Gilde; preclinical candidate deucrictibant selected. |
| 2017–2018 | IND-enabling studies and Phase 1 trials demonstrated acceptable safety, PK/PD and target engagement. |
| 2019 | Phase 2 on-demand program (PHVS416) initiated while ER prophylactic (PHVS719) formulation work advanced. |
| 2021 | Feb Nasdaq IPO raised approximately $190,000,000 to fund clinical expansion. |
| 2022 | FDA placed a US clinical hold on deucrictibant; ex-US trials continued with intensified regulatory and nonclinical workstreams. |
| 2023 | Additional financing and operational expansion supported continued ex-US data generation. |
| 2024 | US clinical activities resumed after FDA concerns resolved; positive Phase 2 data strengthened on-demand and prophylaxis narratives and market cap recovered toward/beyond $1,000,000,000. |
| 2025 | Preparing/initiating pivotal trials for on-demand and prophylaxis with cash runway guided into 2H 2026 after 2024–2025 raises; scaling CMC and commercial planning underway. |
Pivotal program execution
Initiate pivotal on-demand and prophylaxis trials in 2025–2026 with the objective of completing studies in 2026–2027 and preparing NDA/MAA filings for on-demand first.
Regulatory and data strategy
Maintain focused regulatory engagement post-2024 FDA resolution, generate robust pivotal datasets and align global submission strategies to support approvals in major markets.
Commercial and access planning
Scale CMC and manufacturing, develop market access and patient services, and consider regional commercialization partnerships in Europe and the US to support launches.
Pipeline and lifecycle expansion
Explore label expansion into broader bradykinin-mediated angioedema and adjacent rare conditions, and evaluate combination or lifecycle management strategies post-approval.
For additional context on strategic positioning and marketing initiatives, see Marketing Strategy of Pharvaris.
Pharvaris Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Pharvaris Company?
- What is Growth Strategy and Future Prospects of Pharvaris Company?
- How Does Pharvaris Company Work?
- What is Sales and Marketing Strategy of Pharvaris Company?
- What are Mission Vision & Core Values of Pharvaris Company?
- Who Owns Pharvaris Company?
- What is Customer Demographics and Target Market of Pharvaris Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.